Cardioprotective effect of trimetazidine during thrombolytic therapy in patients with acute myocardial infarction.
We studied the cardioprotective effect of anti-ischemic drug trimetazidine in the thrombolytic therapy of acute myocardial infarction. Trimetazidine (60 mg/day) effectively inhibits lipid peroxidation and moderates reperfusion damage to the myocardium assessed by ECG, QRS index of damaged heart, and release of creatine phosphokinase into circulation.